Promising Trends: The Role of SGLT2 Inhibitors in Type 2 Diabetes Treatment and their Cardiovascular Impacts
Vol. 6 No. 2 (2024), Literature Review
Vol. 6 No. 2 (2024)

Promising Trends: The Role of SGLT2 Inhibitors in Type 2 Diabetes Treatment and their Cardiovascular Impacts

Literature Review
https://doi.org/10.36557/2674-8169.2024v6n2p821-829
Published 2024-02-08
José Lucas Moura Vasconcelos
UniFG Guanambi
Antônia de Carvalho Pereira Pinto
Faminas Muriaé
https://orcid.org/0009-0007-7501-6719
Antonio Elcio Santos Silva
UNIFACS
https://orcid.org/0009-0007-6092-1089
Anthonielly Leinat Lima
Universidade de Cuiabá - UNIC
https://orcid.org/0009-0005-8930-7176
Camila Metelo Duarte
Universidade de Cuiaba - UNIC
https://orcid.org/0009-0003-1915-9150
Carlos Eduardo do Carmo Almeida
Faminas Muriaé
César de Brito Parra Batista
Centro Universitário Uninorte
https://orcid.org/0009-0003-9129-8278
Eduarda Medeiros Simsen
Faculdade Pequeno Príncipe
https://orcid.org/0009-0005-1909-4267
Geovana Pirassol Roque
Centro Universitário Ingá
https://orcid.org/0009-0009-2516-0426
Isabela Olivo Pires
Universidade de Cuiabá - UNIC
https://orcid.org/0009-0007-2199-3995
João Pedro Azevedo Druszcz
Universidade Positivo
https://orcid.org/0009-0001-5669-7033
João Victor Sola Barreto Marcelino
Universidade Anhembi Morumbi - UAM
https://orcid.org/0000-0002-1331-0708
João Victor Sola Barreto Marcelino
Universidade Anhembi Morumbi - UAM
https://orcid.org/0000-0002-1331-0708
Julia Borges Barbero
Universidade de Cuiabá - UNIC
https://orcid.org/0009-0001-9921-2286
Laisse Oliveira Barbosa de Melo
UNIFACS
https://orcid.org/0009-0001-3221-0710
Lucas Henrique Matias Dias Pereira
Faminas Muriaé
https://orcid.org/0009-0006-4741-3891
Raí Araújo Dourado Ferreira
UNIFACS
https://orcid.org/0009-0009-6904-0637
Rafael Leituga de Carvalho Cavalcante
Pontifícia Universidade Católica do Rio Grande do Sul - PUCRS
https://orcid.org/0000-0001-6436-3968
Ranielly Mendes Amorim
Faminas Muriaé
https://orcid.org/0009-0001-7731-2323
Rebeka Raquel Feliciano Queiroz
Faminas Muriaé
https://orcid.org/0009-0000-0268-1688
Stephane Izabor de Oliveira Costa
UNIFACS
https://orcid.org/0009-0008-9683-7695
Valentine Ferlin
Universidade de Cuiabá - UNIC
https://orcid.org/0009-0007-9477-7492
Victória Persigili
Universidade Anhembi Morumbi - UAM
https://orcid.org/0009-0005-4677-1788
Wilson Cazarim Neto
Universidade Presidente Antônio Carlos
https://orcid.org/0009-0006-8397-5373
PDF (Português (Brasil))

Keywords

SGLT2 inhibitors

How to Cite

Vasconcelos, J. L. M., Pinto , A. de C. P., Silva , A. E. S., Lima , A. L., Duarte , C. M., Almeida , C. E. do C., Batista , C. de B. P., Simsen, E. M., Roque , G. P., Pires , I. O., Druszcz , J. P. A., Marcelino, J. V. S. B., Marcelino , J. V. S. B., Barbero, J. . . B., Melo , L. O. B. de, Pereira , L. H. M. D., Ferreira , R. A. D., Cavalcante, R. L. de C., Amorim, R. M., Queiroz, R. R. F., Costa , S. I. de O., Ferlin , V., Persigili , V., & Neto , W. C. (2024). Promising Trends: The Role of SGLT2 Inhibitors in Type 2 Diabetes Treatment and their Cardiovascular Impacts. Brazilian Journal of Implantology and Health Sciences, 6(2), 821–829. https://doi.org/10.36557/2674-8169.2024v6n2p821-829
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

This study reviewed the role of sodium-glucose cotransporter 2 (SGLT2) inhibitors in the treatment of type 2 diabetes and their cardiovascular impacts. Through the analysis of clinical studies, including those conducted with empagliflozin, canagliflozin, dapagliflozin, and ertugliflozin, a significant reduction in the risk of adverse cardiovascular events was observed in patients treated with these medications. Additionally, SGLT2 inhibitors were associated with additional benefits, such as reducing the progression of renal disease and hospitalization for heart failure. However, further research is needed to fully understand the mechanisms of action of these medications and their potential long-term adverse effects. In summary, SGLT2 inhibitors represent an important therapeutic option in the management of type 2 diabetes, offering additional cardiovascular and renal benefits beyond glycemic control.

https://doi.org/10.36557/2674-8169.2024v6n2p821-829
PDF (Português (Brasil))

References

Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., ... & Zwiener, I. (2015). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New England Journal of Medicine, 373(22), 2117-2128.

Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., ... & Matthews, D. R. (2017). Canagliflozin and cardiovascular and renal events in type 2 diabetes. New England Journal of Medicine, 377(7), 644-657.

Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., ... & Bhatt, D. L. (2019). Dapagliflozin and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 380(4), 347-357.

McMurray, J. J., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., ... & Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure (DAPA-HF) Trial Committees and Investigators. (2019). Dapagliflozin in patients with heart failure and reduced ejection fraction. New England Journal of Medicine, 381(21), 1995-2008.

Cannon, C. P., Pratley, R., Dagogo-Jack, S., Mancuso, J., Huyck, S., Masiukiewicz, U., ... & Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants with Vascular Disease (VERTIS CV) Trial Investigators. (2020). Cardiovascular outcomes with ertugliflozin in type 2 diabetes. New England Journal of Medicine, 383(15), 1425-1435.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2024 José Lucas Moura Vasconcelos, Antônia de Carvalho Pereira Pinto , Antonio Elcio Santos Silva , Anthonielly Leinat Lima , Camila Metelo Duarte , Carlos Eduardo do Carmo Almeida , César de Brito Parra Batista , Eduarda Medeiros Simsen, Geovana Pirassol Roque , Isabela Olivo Pires , João Pedro Azevedo Druszcz , João Victor Sola Barreto Marcelino, João Victor Sola Barreto Marcelino , Julia Borges Barbero, Laisse Oliveira Barbosa de Melo , Lucas Henrique Matias Dias Pereira , Raí Araújo Dourado Ferreira , Rafael Leituga de Carvalho Cavalcante, Ranielly Mendes Amorim, Rebeka Raquel Feliciano Queiroz, Stephane Izabor de Oliveira Costa , Valentine Ferlin , Victória Persigili , Wilson Cazarim Neto